everlinQ endoAVF Post Market Study
A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 100 participants.
Also called NCT02682420
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT02682420
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada, Germany, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT02682420. Allocation not applicable; no masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2019-08 (actual). Results posted on 2021-11-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- everlinQ endoAVF Post Market Study
- Condition
- Chronic Kidney Disease
- Intervention (Device)
- everlinQ endoAVF System
- Lead sponsor
- C. R. Bard
Record details
- Record id
cardio:ct-nct02682420- Content hash
a1919fb456d9571887b719c28029f5cb058025634ad1f68ecff2769e47e37dbf